跳至主要内容
临床试验/NCT01008774
NCT01008774已完成不适用

A Comparison of Different Scalp Cooling Systems for the Prevention of Chemotherapy Induced Alopecia

Sanofi1 个研究点 分布在 1 个国家目标入组 239 人开始时间: 2009年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Sanofi
入组人数
239
试验地点
1
主要终点
Grade III or IV alopecia according to the WHO criteria

研究概览

简要总结

Primary objective:

  • Rate of complete chemotherapy induced alopecia (WHO grade III or IV, physician grading)

Secondary objective:

  • Compliance to scalp cooling procedure
  • Received number of cycles of chemotherapy in each subgroup
  • Patient perception of scalp cooling procedure
  • Side effects of scalp cooling systems

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Any solid tumor malignancy receiving docetaxel (Taxotere®) 1st line chemotherapy treatment with the exception of regimen containing concomitant anthracycline treatment; sequential anthracycline/docetaxel treatment is permitted.
  • Performance Status ECOG <= 2
  • Absence of alopecia at inclusion

排除标准

  • Chemotherapy regimen including concomitant anthracycline treatment
  • Raynaud's disease or phenomenon
  • Cold agglutinin disease
  • Cryoglobulinemia
  • Cryofibrinogenemia
  • Scalp metastasis
  • Pregnancy or Lactation
  • Preexisting alopecia of any grade; notably androgenetic alopecia

结局指标

主要结局

Grade III or IV alopecia according to the WHO criteria

时间窗: D1 of each cycle and D+21 after last cycle of chemotherapy

次要结局

  • Side effects of scalp cooling systems(D1 of each cycle and D+21 after last cycle of chemotherapy)
  • Compliance to scalp cooling procedure(D1 of each cycle and D+21 after last cycle of chemotherapy)

研究者

发起方
Sanofi
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验